COMMUNIQUÉS West-GlobeNewswire

Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data at 14th Eilat Conference
15/05/2018
Company to Hold Conference Call at 8:00 am ET Today XEN1101 Pilot TMS-EEG Data Demonstrates Statistically Significant Effect of 20mg Dose versus Baseline (p<0.01) and Greater Effect on TMS-EMG Resting Motor Threshold [...]
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
15/05/2018
Company to Hold Conference Call at 8:00 am ET Today Preliminary Phase 1 Clinical Data Support Drug Exposure Levels Higher than Required in Pre-clinical Efficacy Models with Excellent Tolerability and Safety New Pre- [...]
PotNetwork Holdings, Inc. Exceeds $2 Million in Revenues in April 2018, Realizing a 98% Increase Over April 2017
15/05/2018
Reflecting the Company’s Commitment to Excellence in Research, Innovation and Consumer Satisfaction, Exponential Results Continue FT LAUDERDALE, Fla., May 15, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork [...]
Invivoscribe Releases the LymphoTrack Dx TRB Assay as CE-Marked IVD Kit, Completing the NGS Clonality Suite for the MiSeq Platform
15/05/2018
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies Inc., a global company with decades of experience providing clonality and biomarker test solutions for the fields of oncology and personalized [...]
Transactions in relation to share buyback program
15/05/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
United States Commerce Department Invites ViaDerma to Participate in Official Trade Mission to India
15/05/2018
LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce their participation in the upcoming Beauty & Wellness Executive Service Program , hosted by the [...]
Navamedic ASA: Notice of Annual General Meeting
15/05/2018
The Annual General Meeting in Navamedic ASA will take place on Thursday 7 June 2017 at 14.00 at Felix Konferansesenter, Bryggetorget 3, Oslo. Please find attached the annual report. Notice of the meeting, has been [...]
Update: Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 30, 2018
15/05/2018
Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent necrotizing enterocolitis, has [...]
LIDDS broadens the scope of its technology platform by verifying NanoZolid® as subcutaneous depot for systemic delivery
15/05/2018
UPPSALA, SWEDEN - LIDDS AB (publ) is today unveiling new animal data which demonstrates that subcutaneously injected NanoZolid® can act as a depot for systemic delivery of pharmaceutically active drugs. A two week [...]
Navamedic ASA: Notice of Annual General Meeting
15/05/2018
The Annual General Meeting in Navamedic ASA will take place on Thursday 7 June 2017 at 14.00 at Felix Konferansesenter, Bryggetorget 3, Oslo. Please find attached the annual report. Notice of the meeting, has been [...]
Shire plc : Rule 2.9 Announcement
15/05/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 15 May 2018 Shire [...]
PCI Biotech to present at BioEquity Europe
15/05/2018
Oslo, Norway, May 15, 2018 PCI Biotech (OSE: PCIB ), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the Company at [...]
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 30, 2018
15/05/2018
Message from the CEO During the past year, IBT passed the most important milestones in the company's history. The company's drug candidate, IBP-9414, which we believe will prevent necrotizing enterocolitis, has [...]
Alavida Health Selected for C100’s 48 Hours in the Valley
15/05/2018
VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Alavida Health , a science and technology-based treatment program for alcohol addiction, announced today that they have been selected to participate in the [...]
Basilea reports launch of antibiotic Zevtera (ceftobiprole) in Saudi Arabia by Hikma Pharmaceuticals LLC
15/05/2018
Basel, Switzerland, May 15, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its partner Hikma Pharmaceuticals LLC has launched Basilea's hospital antibiotic Zevtera ® (ceftobiprole) in Saudi Arabia. [...]
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
15/05/2018
ARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya ® *) in clearing of Stelara ® *-resistant psoriatic plaques[1] This is the 100 th trial with [...]
Fagron shareholders approve all proposed resolutions
15/05/2018
Nazareth (Belgium) / Rotterdam (The Netherlands), 15 May 2018 Regulated information Fagron announces today that the annual general meeting of shareholders and the extraordinary shareholders meeting, both held on 14 May [...]
Probiodrug AG reports First Quarter 2018 Business Update
15/05/2018
Probiodrug AG reports First Quarter 2018 Business Update HALLE (SAALE), Germany, 15 May 2018 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions [...]
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
15/05/2018
Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM Merger Corporation (" [...]

Pages